The in vitro activity of thienamycin was tested against 135 aerobic and anaerobic bacteria. The compound was highly active against resistant gramnegative bacilli and penicillin-resistant Straphylococcus aureus. The antianaerobic spectrum of the drug seemed to be comparable to that of metronidazole. 
The measured concentration was within 15% of the calculated level of drug in all experiments. The following concentrations of antimicrobial agents (in micrograms per milliliter) were used: thienamycin, 8 8 pg of thienamycin per ml were subsequently tested at higher concentrations of up to 64 pg/ml.
Organisms. The facultative aerobic bacteria were isolated at Tufts-New England Medical Center clinical bacteriology laboratory. Eight strains of Serratia marcescens were obtained from Grace Thorne (Boston, Mass.). Identification of the isolates was carried out by using the criteria of Blair et al. (1) .
The anaerobic bacteria were isolated from clinical specimens processed in the Tufts Anaerobic Research Laboratory by using previously described techniques (7) . Six highly penicillin-resistant isolates of Bacteroides fragilis were obtained from Carl-Eric Nord, National Bacteriology Laboratory, Stockholm, Sweden. The anaerobic organisms were identified according to the criteria of the Anaerobe Laboratory Manual (4) . Control organisms included an Escherichia coli, ATCC 25922, and a Staphylicoccus aureus, ATCC 25923; Bacteroides vulgatus strain 10, obtained from Vera Sutter (Los Angeles, Calif.), has been used routinely as a control in our laboratory in the susceptibility testing of anaerobes.
Determination ofminimum inhibitory concentrations. The susceptibility of the organims to the antimicrobial agents was tested by a broth dilution microtiter technique, as previously described (2) . The medium used for testing the facultative bacteria was Mueller-Hinton broth. The anaerobic isolates were tested in brain heart infusion broth enriched with yeast extract (0.5%), hemin (0.005%) and vitamin K (1 ug/ml). The inoculum was prepared by diluting a latelogarithmic-phase broth culture to yield approximately 3 x 10' colony-forming units per ml. Serial twofold dilutions of the antimicrobial agents were made in disposable plastic plates with an automatic dilutor (Cooke Engineering Co. [Dynatech Corp.] Alexandria, Va.). The bacterial inoculum (0.05 ml) was added to 0.05 ml of the antimicrobial solution to yield a total volume of 0.1 ml in each well. The plates with the facultative organisms were incubated in air, while the anaerobic bacteria were incubated in an anaerobic chamber at 37°C in an atmosphere of 85% N2, 10% H2, and 5% CO2.
The minimal inhibitory concentration was that level of drug which showed no visible turbidity or deposit at the bottom of the microtiter well. The minimal bactericidal concentration was obtained by subculturing 0.001 ml from each well onto antibiotic-free solid medium; Mueller-Hinton agar was used for the facultative aerobes, and brain heart infusion agar with hemin and 5% Thienamycin showed good activity against the anaerobic bacteria tested ( Table 1 ). All isolates of B. fragilis, including six highly penicillin-resistant strains (minimal inhibitory concentration, >128 jig/ml), were inhibited by 1 jg/ml.
The antianaerobic activity of this new compound was slightly better than that of clindamycin and metronidazole and distinctly better than that of penicillin G. The minimal bactericidal concentration was within one dilution with all the organisms tested. DISCUSSION Thienamycin is a novel cell wall-active antibiotic which exhibits broad activity against gram-positive and -negative aerobic and anaerobic bacteria. Its aerobic spectrum includes most gram-negative bacilli tested, including E. coli, Pseudomonas, and S. aureus. The higher concentration of the drug needed to inhibit selected strains of Serratia and Proteus were unexpected, considering previous data (Kropp et al., 16th ICAAC, Abstr. no. 228). The possibility that the drug was inactivated during testing was ruled out by a spectophotometric assay and by the results with control organisms included in the tests. The mechanism of decreased susceptibility of Serratia and Proteus is unknown. It may be a decreased penetration to the active site, an absence of thienamycin-binding proteins which have been demonstrated in E. coli, or an inactivation of the drug by the organism (6) .
Thienamycin shows excellent activity against anaerobic bacteria and is comparable to metronidazole, the most active drug presently available for inhibition of anaerobes. The development of this new agent for the treatment of pure anaerobic and mixed anaerobic-aerobic infections is important because the current drugs are limited to chloramphenicol, clindamycin, carbenicillin, metronidazole, and cefoxitin (3). The ANTIMICROB. AGENTS CHEMOTHER. first two agents have significant toxicity, and recent data indicate that clindamycin resistance in B. fragilis is being encountered with increasing frequency in Europe (personal communication, S. Tabaqchali, London) and occasionally in the United States (5). High-level resistance to penicillin, including carbenicillin, is being encountered in approximately 10% of the isolates in recent susceptibility studies (8) . The two experimental agents, metronidazole and cefoxitin, offer promise in the treatment of anaerobic infections. However, the forner agent has a spectrum which is restricted primarily to anaerobic bacteria, and its known mutagenic potential is also disturbing. Cefoxitin is a relatively safe beta-lactam antibiotic with good activity against aerobic and anaerobic bacteria, but there are some strains of Bacteroides which are not inhibited, even at drug concentratio-ns of 64 ,ug/ml (9).
Because of the instability of the parent compound in aqueous solution, congeners of thienamycin are being sought that would have increased stability and also retain excellent antimicrobial activity. If such a compound can be developed, it will signal a new era in the chemotherapy of bacterial infections.
